BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15547484)

  • 1. [Hydroxyurea treatment for unresectable meningioma].
    Fuentes S; Chinot O; Dufour H; Paz-Paredes A; Métellus P; Barrie-Attarian M; Grisoli F
    Neurochirurgie; 2004 Sep; 50(4):461-7. PubMed ID: 15547484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
    Mason WP; Gentili F; Macdonald DR; Hariharan S; Cruz CR; Abrey LE
    J Neurosurg; 2002 Aug; 97(2):341-6. PubMed ID: 12186462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
    Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study.
    Hahn BM; Schrell UM; Sauer R; Fahlbusch R; Ganslandt O; Grabenbauer GG
    J Neurooncol; 2005 Sep; 74(2):157-65. PubMed ID: 16193387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up.
    Newton HB; Scott SR; Volpi C
    Br J Neurosurg; 2004 Oct; 18(5):495-9. PubMed ID: 15799152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma.
    Chamberlain MC
    J Neurooncol; 2012 Apr; 107(2):315-21. PubMed ID: 22127733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-resectable slow-growing meningiomas treated by hydroxyurea.
    Loven D; Hardoff R; Sever ZB; Steinmetz AP; Gornish M; Rappaport ZH; Fenig E; Ram Z; Sulkes A
    J Neurooncol; 2004; 67(1-2):221-6. PubMed ID: 15072471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea chemotherapy for unresectable or residual meningioma.
    Newton HB; Slivka MA; Stevens C
    J Neurooncol; 2000 Sep; 49(2):165-70. PubMed ID: 11206012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of high risk or recurrent meningiomas with hydroxyurea.
    Rosenthal MA; Ashley DL; Cher L
    J Clin Neurosci; 2002 Mar; 9(2):156-8. PubMed ID: 11922703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series.
    Chamberlain MC; Johnston SK
    J Neurooncol; 2011 Sep; 104(3):765-71. PubMed ID: 21318318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of unresectable skull base meningiomas with somatostatin analogs.
    Schulz C; Mathieu R; Kunz U; Mauer UM
    Neurosurg Focus; 2011 May; 30(5):E11. PubMed ID: 21529167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea for treatment of unresectable meningiomas.
    Schrell UM; Rittig MG; Koch U; Marschalek R; Anders M
    Lancet; 1996 Sep; 348(9031):888-9. PubMed ID: 8826822
    [No Abstract]   [Full Text] [Related]  

  • 14. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
    Schrell UM; Rittig MG; Anders M; Kiesewetter F; Marschalek R; Koch UH; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):845-52. PubMed ID: 9126901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas.
    Chamberlain MC; Glantz MJ
    Cancer; 2008 Oct; 113(8):2146-51. PubMed ID: 18756531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
    Reardon DA; Norden AD; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Sampson JH; Gururangan S; Peters KB; McLendon RE; Norfleet JA; Lipp ES; Drappatz J; Wen PY; Friedman HS
    J Neurooncol; 2012 Jan; 106(2):409-15. PubMed ID: 21938530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea chemotherapy in the treatment of meningiomas.
    Newton HB
    Neurosurg Focus; 2007; 23(4):E11. PubMed ID: 17961035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies.
    Karsy M; Hoang N; Barth T; Burt L; Dunson W; Gillespie DL; Jensen RL
    World Neurosurg; 2016 Feb; 86():210-9. PubMed ID: 26428319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.
    Grunberg SM; Weiss MH; Russell CA; Spitz IM; Ahmadi J; Sadun A; Sitruk-Ware R
    Cancer Invest; 2006 Dec; 24(8):727-33. PubMed ID: 17162554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of hydroxyurea as an adjuvant treatment after Gamma knife radiosurgery for atypical (WHO grade II) meningiomas.
    Abdel Karim K; El Shehaby A; Emad R; Reda W; El Mahdy M; Ghali R; Nabeel A
    J Egypt Natl Canc Inst; 2018 Jun; 30(2):69-72. PubMed ID: 29691095
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.